marked.bio

mutant-selective PI3Kα inhibitor · small molecule

STX-478

1 active trials, targeting mutant PI3Kα. Not approved for any biomarker on marked.bio yet.

Also known as LY4064809.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 1 1 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of STX-478.

  1. Eli Lilly 1

Trials

1 of 1 trials shown

  1. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    Recruiting Phase 3 Eli Lilly Started 2025Primary completion 2029-05 NCT07174336

    STX-478ribociclibpalbociclib FDA EUabemaciclibanastrozoleletrozoleExemestanefulvestrant FDA EU

    Have evidence of an activating PIK3CA mutation, detected in tumor or blood samples using an appropriate assay.

    PIK3CA activating mutationBreast Neoplasms, Neoplasm Metastasis